Randomized, Double-Blind, Double-Dummy, Active-Controlled, Cross-Over Study Evaluating the Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura

Trial Profile

Randomized, Double-Blind, Double-Dummy, Active-Controlled, Cross-Over Study Evaluating the Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Sep 2017

At a glance

  • Drugs Sumatriptan (Primary) ; Sumatriptan
  • Indications Migraine with aura; Migraine without aura
  • Focus Registrational; Therapeutic Use
  • Acronyms COMPASS
  • Sponsors Avanir Pharmaceuticals; OptiNose
  • Most Recent Events

    • 10 Sep 2017 Results (n=259) comparing efficacy and tolerability of sumatriptan tablets versus sumatriptan delivered intranasally in adult patients with acute migraine with or without aura, were presented at the 2017 International Headache Society.
    • 07 Sep 2017 Results (n=259) of post hoc analysis assessing the trajectories of relief of pain and disability following treatment with AVP-825 published in the Headache
    • 11 Jun 2017 Results (n=259) assessing the complex relationships among treatment, pain, and disability using bivariate latent curve models, presented at the 59th Annual Scientific Meeting of the American Headache Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top